Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with IBD
Digestive Diseases and Sciences · 2025
DOI: 10.1007/s10620-024-08792-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Digestive Diseases and Sciences, 2025. Verfasst von Kush Fansiwala und 1 weiteren Autor:innen. Beteiligte Einrichtung: Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. kfa…. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Small molecule Janus kinase (JAK) inhibitors have revolutionized the management of ulcerative colitis (UC) and Crohn's disease (CD) through their low immunogenicity, safety, and consistent pharmacologic response that are superior to existing therapeutic options. In this perspective, we highlight existing evidence supporting the use of currently approved JAK inhibitors (upadacitinib, tofacitinib, and filgotinib) for UC or CD, additionally emphasizing the evidence for their use in related autoimmune conditions such as rheumatoid arthritis and spondyloarthropathies. Our perspective concludes with a review of the existing comparative effectiveness literature, which positions JAK inhibitors, particularly upadacitinib, favorably compared with other biologic therapies. This perspective is paired with a companion publication highlighting the origins and development of JAK inhibitors and a more in-depth review of their pathophysiologic mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. kfansiwala@mednet.ucla.edu.
- Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Zitieren
APA
Fansiwala, K., & Sauk, J. S. (2025). Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with IBD. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-024-08792-0
Vancouver
Fansiwala K, Sauk JS. Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with IBD. Digestive Diseases and Sciences. 2025. doi:10.1007/s10620-024-08792-0
BibTeX
@article{Fansiwala2025,
author = {Fansiwala, Kush and Sauk, Jenny S},
title = {Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with IBD},
journal = {Digestive Diseases and Sciences},
year = {2025},
doi = {10.1007/s10620-024-08792-0}
}
EUVIMED